ATE400819T1 - Zubereitungen mit kontrollierter freisetzung - Google Patents

Zubereitungen mit kontrollierter freisetzung

Info

Publication number
ATE400819T1
ATE400819T1 AT03809236T AT03809236T ATE400819T1 AT E400819 T1 ATE400819 T1 AT E400819T1 AT 03809236 T AT03809236 T AT 03809236T AT 03809236 T AT03809236 T AT 03809236T AT E400819 T1 ATE400819 T1 AT E400819T1
Authority
AT
Austria
Prior art keywords
matrix
release
agent
controlled release
release preparations
Prior art date
Application number
AT03809236T
Other languages
English (en)
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Ouzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Original Assignee
Labopharm Inc
Labopharm Europe Ltd
Labopharm Barbados Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc, Labopharm Europe Ltd, Labopharm Barbados Ltd filed Critical Labopharm Inc
Application granted granted Critical
Publication of ATE400819T1 publication Critical patent/ATE400819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03809236T 2002-10-25 2003-10-27 Zubereitungen mit kontrollierter freisetzung ATE400819T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50906202P 2002-10-25 2002-10-25
US28102602A 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
ATE400819T1 true ATE400819T1 (de) 2008-07-15

Family

ID=34976756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809236T ATE400819T1 (de) 2002-10-25 2003-10-27 Zubereitungen mit kontrollierter freisetzung

Country Status (19)

Country Link
EP (1) EP1558935B1 (de)
JP (1) JP2006507276A (de)
KR (1) KR101120729B1 (de)
AT (1) ATE400819T1 (de)
AU (1) AU2003275854B9 (de)
BR (1) BR0315657A (de)
CA (1) CA2503361C (de)
DE (1) DE60322091D1 (de)
DK (1) DK1558935T3 (de)
EC (1) ECSP055748A (de)
ES (1) ES2310686T3 (de)
HK (1) HK1086475A1 (de)
MX (1) MXPA05004410A (de)
NO (1) NO20052515L (de)
NZ (1) NZ539869A (de)
PT (1) PT1558935E (de)
RU (1) RU2333745C2 (de)
SI (1) SI1558935T1 (de)
WO (1) WO2004038428A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
EP1917000A2 (de) 2005-07-07 2008-05-07 Farnam Companies, Inc. Pharmazeutische zusammensetzungen mit verzögerter freisetzung für hoch wasserlösliche arzneimittel
ES2389666T3 (es) * 2005-09-09 2012-10-30 Angelini Labopharm, Llc Composición de trazodona para una administración de una vez al día
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
HUE029173T2 (hu) 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
CN100387988C (zh) * 2006-07-25 2008-05-14 山东省医药工业研究所 一种布洛伪麻那敏复方制剂的含量检测方法
AU2008213744B2 (en) 2007-02-09 2013-12-05 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
MX336494B (es) 2007-10-16 2016-01-21 Paladin Labs Inc Composicion de bicapas para la liberacion controlada de acetaminofeno y tramadol.
PT2293794E (pt) 2008-05-27 2013-07-10 Univ Melbourne Métodos de tratamento de mamíferos com disfunções da trompa de eustáquio
EP2448406B1 (de) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
EP2488029B1 (de) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur abschreckung vor missbrauch
EP2563349A4 (de) * 2010-04-23 2014-03-19 Paladin Labs Inc Nicht-intravenöse darreichungsform aus einer festen formulierung eines flüssigen biologisch wirkstoffs und verwendungen davon
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
CA2270975C (en) * 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
EP1248599B1 (de) * 2001-01-31 2007-12-05 Evonik Röhm GmbH Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen

Also Published As

Publication number Publication date
KR101120729B1 (ko) 2012-04-23
PT1558935E (pt) 2008-10-16
EP1558935A2 (de) 2005-08-03
RU2333745C2 (ru) 2008-09-20
DK1558935T3 (da) 2008-11-17
CA2503361A1 (en) 2004-05-06
WO2004038428A3 (en) 2005-06-09
NZ539869A (en) 2007-09-28
EP1558935B1 (de) 2008-07-09
NO20052515D0 (no) 2005-05-25
CA2503361C (en) 2012-02-28
KR20050088281A (ko) 2005-09-05
RU2005115883A (ru) 2006-01-27
HK1086475A1 (en) 2006-09-22
WO2004038428A2 (en) 2004-05-06
BR0315657A (pt) 2005-09-13
SI1558935T1 (sl) 2008-12-31
DE60322091D1 (de) 2008-08-21
AU2003275854B2 (en) 2008-09-11
ECSP055748A (es) 2005-08-11
MXPA05004410A (es) 2005-11-23
JP2006507276A (ja) 2006-03-02
AU2003275854A1 (en) 2004-05-13
ES2310686T3 (es) 2009-01-16
AU2003275854B9 (en) 2009-08-27
NO20052515L (no) 2005-05-25

Similar Documents

Publication Publication Date Title
NO20052515L (no) Frigjoringskontrollerte sammensetninger
ATE512659T1 (de) Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
MX9707585A (es) Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
DE69229881D1 (de) Tablette mit verzögerter freisetzung
BR0215262A (pt) Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
DE60132077D1 (de) Vitaminzusammenstellung mit verzögerter freigabe
ME00482B (me) Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje
GEP20074022B (en) Pharmaceutical formulations comprising oxycodone and naloxone
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
KR930003906A (ko) 약학적 구상 제형
IE881195L (en) Ibuprofen sustained release matrix
TWI235068B (en) Sustained-release pharmaceutical composition
ME00391B (me) Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
RS54929B1 (sr) Formulacija i metod obložene tablete
WO2004064815A8 (en) Oral dosage formulation
ATE79029T1 (de) Arzneimittel mit kontrollierter wirkstoffabgabe.
DE60233760D1 (de) Netzwerkeinrichtungs-treiberarchitektur
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
ES2078061T3 (es) Material en particulas que comprende unas particulas revestidas de nitruro de boro, util en composiciones cosmeticas y procedimiento para su preparacion.
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
DE502007002695D1 (de) Retardtabletten mit Hydromorphon
DE60023107D1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
ATE185266T1 (de) Schnell auflösende orale darreichungsform

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1558935

Country of ref document: EP